High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience.
Patients with aggressive non-Hodgkin's lymphoma (NHL) who relapse after initial therapy have a poor prognosis and with standard dose salvage therapy the outlook remains poor. In this work we examine the patient characteristics and outcome of patients with aggressive NHL treated with HDT and autologous transplantation at our Institute from 1982 to 1999. A retrospective analysis was performed examining patient characteristics, prior chemotherapy regimens, pretransplant disease status, HDT regimen, source of stem cells, time for hematopietic recovery, complications of transplantation, response rates, overall survival (OS) and relapse-free survival (RFS). One hundred and thirty-four patients with aggressive NHL were treated with estimated 10-year OS and RFS rates of 50% and 66%, respectively. Disease status (sensitive vs. refractory) pre-HDT was the most powerful predictive parameter for OS and RFS, at both univariate and multivariate analysis. For the entire cohort, transplant-related mortality was only 3.5% without evidence of second malignancies. Our results confirm that HDT with autologous transplantation is associated with a durable RFS in a remarkable proportion of aggressive NHL patients with very low global early and late toxicity. Improved patient selection, transplant timing, ongoing improvements in supportive care, and selected phase III trials should increase outcomes further.
Zinzani
Pier Luigi
PL
Institute of Hematology and Medical Oncology L. e A. Seràgnoli, University of Bologna, Italy. plzinzo@med.unibo.it
Tani
Monica
M
Gabriele
Annalisa
A
Gherlinzoni
Filippo
F
De Vivo
Antonello
A
Ricci
Paolo
P
Bandini
Giuseppe
G
Lemoli
Roberto Massimo
RM
Motta
Maria Rosa
MR
Rizzi
Simonetta
S
Guidice
Valeria
V
Zompatori
Maurizio
M
Stefoni
Vittorio
V
Alinari
Lapo
L
Musuraca
Gerardo
G
Marchi
Enrica
E
Bassi
Simona
S
Conte
Roberto
R
Pileri
Stefano
S
Tura
Sante
S
Baccarani
Michele
M
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D017077:Culture Media, Conditioned / Q000494:pharmacology; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors; D014182:Transplantation, Autologous / Q000379:methods*; D016896:Treatment Outcome
D017077:Culture Media, Conditioned